leadf
logo-loader
viewMaxCyte Inc

Maxcyte deal with APEIRON Biologics 'highlights value of its Flow Electroporation technology'

Proactive Research analyst Emma Ulker discusses MaxCyte’s (LON:MXCT) new clinical and commercial licence agreement with Apeiron Biologics. It allows the use of MaxCyte’s proprietary Flow Electroporation technology for manufacturing Apeiron’s gene-silencing siRNA therapy, APN401, for clinical studies. Ulker says the agreement highlights MXCT’s expertise and the value of its Flow Electroporation technology, which is rapidly being adopted as the gold standard in non-viral cell and gene engineering

 

Click here to read our latest research update on MaxCyte Inc

Quick facts: MaxCyte Inc

Price: 430 GBX

AIM:MXCT
Market: AIM
Market Cap: £331.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 08/18/2020

2 min read